Vectors including foreign genes and negative selective markers

Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 691, 4351723, A61K 4800, C12N 510

Patent

active

059253452

ABSTRACT:
A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.

REFERENCES:
patent: 5358866 (1994-10-01), Mullen et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5529774 (1996-06-01), Barba et al.
Hellerman, et al., Proc. Nat. Acad. Sci., vol. 81, pp. 5340-5344 (Sep. 1984).
Moolten, Cancer Research, vol. 46, pp. 5276-5281 (Oct. 1986).
Selden, et al., Science, vol. 236, pp. 714-718 (May 8, 1987).
Borelli, et al., Proc. Nat. Acad. Sci., vol. 85, pp. 7572-7576 (Oct. 1988).
Breakfield, Neurobiology of Aging, vol. 10, pp. 647-648 (1989).
Heyman, et al., Proc. Nat. Acad. Sci., vol. 86, pp. 2698-2702 (Apr. 1989).
Borelli, et al., Nature, vol. 339, pp. 538-541 (Jun. 15, 1989).
Moolten, et al., Human Gene Therapy, vol. 1, pp. 125-134 (1990).
Zwiebel, et al., Annals New York Academy of Sciences, vol. 618, pp. 394-404 (1990).
Moolten, et al., J. Nat. Cancer Inst., vol. 82, No. 4, pp. 297-300 (Feb. 21, 1990).
Gansbacher, et al., J. Cell Biochem., Supp. 15G, Abstract S218 (Apr. 6-Apr. 25, 1991).
Fleischman, Am. J. Med. Sci., vol. 301, No. 5, pp. 353-363 (1991).
Plautz, et al., The New Biologist, vol. 3, No. 7, pp. 709-715 (Jul. 1991).
Cardin et al., "Inhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E", Bichem. Biophys. Res. Commun., 154(2): 741-745, (1988).
Jackson et al., "Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII", Proc. Nat. Acad. Sci. USA, 81: 2945-2949, (1984).
"Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," Orkin and Motulsky, Co-chairs, Dec. 7, 1995.
Crystal, Science 270:404-410 (1995).
K.-i. Arai et al., Ann. Rev. Biochem. 59:783-836 (1990).
Gilboa et al., Trends in Genetics 10(4):139-144 (1994).
Daar et al., Proc. Natl. Acad. Sci. USA 87:6574-6578 (1990).
Johnston et al., Science 260:1286-1293 (1993).
Kay et al., Proc. Natl. Acad. Sci. USA 91:2353-2357 (1994).
Smith et al., Nature Genetics 5:397-402 (1993).
Lozier et al., JAMA 271(1):47-51 (1994).
Connelly et al., Human Gene Therapy 6:185-193 (1995).
Hoeben et al., Hum. Gene Ther. 4:179-186 (1993).
Coghlan, New Scientist 148:14-15 (1995).
Kozarsky et al., J. Biol. Chem. 269(18):13695-13702 (1994).
Kozarsky et al., Nature Genetics 13:54-62 (1996).
Fenjves et al., Human Gene Therapy 5:1241-1248 (1994).
Kashyap et al., J. Clinical Investigation 96:1612-1620 (1995).
Barinaga, Science 266:1326 (1994).
Kolata, "In the Rush Toward Gene Therapy, Some See a High Risk of Failure," The New York Times, Jul. 25, 1995, Sec. C3.
Blaese, Hospital Practice 30(12):37-45 (1995).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Vectors including foreign genes and negative selective markers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vectors including foreign genes and negative selective markers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors including foreign genes and negative selective markers will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1319893

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.